SIM
IOVA icon

Spark Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Spark Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-18,850
Closed -$521K – 450
2019
Q4 		$521K Sell
18,850
-19,450
-51% -$442K 0.06% 344
2019
Q3 		$697K Hold
38,300
– – 0.09% 219
2019
Q2 		$939K Buy
+38,300
New +$577K 0.07% 305

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Spark Investment Management's IOVA Position: Q1 2020 in Review

Spark Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2020, closing a stake of 18,850 shares — an estimated $521K sold.

Spark Investment Management first reported a position in IOVA in Q2 2019 and held it in 3 quarters. The position peaked at $939K in Q2 2019. 219 funds tracked by Wall St. Rank hold IOVA as of Q1 2020.

  • Spark Investment Management reported no remaining Iovance Biotherapeutics position as of Q1 2020 after selling out during the quarter.
  • Spark Investment Management sold 18,850 Iovance Biotherapeutics shares in Q1 2020, an estimated $521K.
  • Spark Investment Management first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 3 quarters.
  • Spark Investment Management's Iovance Biotherapeutics position peaked at $939K in Q2 2019.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2020.

Based on Spark Investment Management's 13F filing for Q1 2020, filed 12 May 2020.